Elinogrel (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Elinogrel" in English language version.

refsWebsite

Global rank English rank

2^nd place

2^nd place

4^th place

4^th place

195^th place

302^nd place

1semanticscholar.org

11^th place

8^th place

1web.archive.org

1^st place

1^st place

1insciences.org

low place

low place

14^th place

14^th place

1bioportfolio.com

low place

low place

archive.today

"Novartis drops elinogrel outright". BioPortfolio. Archived from the original on 2012-07-29.

bioportfolio.com

"Novartis drops elinogrel outright". BioPortfolio. Archived from the original on 2012-07-29.

doi.org

Siller-Matula JM, Krumphuber J, Jilma B (February 2010). "Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases". British Journal of Pharmacology. 159 (3): 502–17. doi:10.1111/j.1476-5381.2009.00555.x. PMC 2828016. PMID 20050853.
Gurbel PA, Kereiakes D, Tantry US (November 2010). "Elinogrel potassium: Receptor antagonist antiplatelet therapy". Drugs of the Future. 35 (11): 885–92. doi:10.1358/dof.2010.35.11.1529823. S2CID 79785538.
Michelson AD (2011). "Advances in antiplatelet therapy". Hematology. American Society of Hematology. Education Program. 2011: 62–9. doi:10.1182/asheducation-2011.1.62. PMID 22160013.

insciences.org

"Novartis gains worldwide rights to elinogrel, a Phase II anti-clotting compound with potential to reduce risk of heart attack". Insciences. Archived from the original on 2014-07-14.

nih.gov

pubmed.ncbi.nlm.nih.gov

Siller-Matula JM, Krumphuber J, Jilma B (February 2010). "Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases". British Journal of Pharmacology. 159 (3): 502–17. doi:10.1111/j.1476-5381.2009.00555.x. PMC 2828016. PMID 20050853.
Michelson AD (2011). "Advances in antiplatelet therapy". Hematology. American Society of Hematology. Education Program. 2011: 62–9. doi:10.1182/asheducation-2011.1.62. PMID 22160013.

ncbi.nlm.nih.gov

Siller-Matula JM, Krumphuber J, Jilma B (February 2010). "Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases". British Journal of Pharmacology. 159 (3): 502–17. doi:10.1111/j.1476-5381.2009.00555.x. PMC 2828016. PMID 20050853.

semanticscholar.org

api.semanticscholar.org

Gurbel PA, Kereiakes D, Tantry US (November 2010). "Elinogrel potassium: Receptor antagonist antiplatelet therapy". Drugs of the Future. 35 (11): 885–92. doi:10.1358/dof.2010.35.11.1529823. S2CID 79785538.

web.archive.org

"Novartis gains worldwide rights to elinogrel, a Phase II anti-clotting compound with potential to reduce risk of heart attack". Insciences. Archived from the original on 2014-07-14.

who.int

"International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 63" (PDF). World Health Organization. pp. 50–1. Retrieved 1 December 2016.